137 related articles for article (PubMed ID: 9394322)
1. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure.
Boccardo P; Melacini D; Rota S; Mecca G; Boletta A; Casiraghi F; Gianese F
Nephrol Dial Transplant; 1997 Nov; 12(11):2349-54. PubMed ID: 9394322
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.
Skagerlind MSE; Stegmayr BG
Eur J Clin Pharmacol; 2018 Mar; 74(3):267-274. PubMed ID: 29198062
[TBL] [Abstract][Full Text] [Related]
5. Haemodialysis without anticoagulant: haemostasis parameters, fibrinogen kinetic, and dialysis efficiency.
Româo JE; Fadil MA; Sabbaga E; Marcondes M
Nephrol Dial Transplant; 1997 Jan; 12(1):106-10. PubMed ID: 9027783
[TBL] [Abstract][Full Text] [Related]
6. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients.
Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M
J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236
[TBL] [Abstract][Full Text] [Related]
7. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients.
Nurmohamed MT; Knipscheer HC; Stevens P; Krediet RT; Roggekamp MC; Berckmans RJ; ten Cate JW
Clin Nephrol; 1993 Mar; 39(3):166-71. PubMed ID: 8462205
[TBL] [Abstract][Full Text] [Related]
9. Haemodialysis in patients treated with oral anticoagulant: should we heparinize?
Krummel T; Scheidt E; Borni-Duval C; Bazin D; Lefebvre F; Nguyen P; Hannedouche T
Nephrol Dial Transplant; 2014 Apr; 29(4):906-13. PubMed ID: 24459138
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure.
Gianese F; Nurmohamed MT; Imbimbo BP; Büller HR; Berckmans RJ; Ten Cate JW
Br J Clin Pharmacol; 1993 Mar; 35(3):335-9. PubMed ID: 8471416
[TBL] [Abstract][Full Text] [Related]
12. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
[TBL] [Abstract][Full Text] [Related]
13. Clinical study on low-molecular weight heparin infusion as anticoagulation for nocturnal home haemodialysis.
Wong SS; Lau WY; Ng ML; Chan SY; Chan SF; Chan PK; Wan CK; Cheng YL
Nephrology (Carlton); 2018 Apr; 23(4):317-322. PubMed ID: 28052451
[TBL] [Abstract][Full Text] [Related]
14. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE
Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314
[TBL] [Abstract][Full Text] [Related]
15. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis.
Simpson HK; Baird J; Allison M; Briggs JD; Rowe PA; Welsh M; Macdougall AI; Grant AC; Lowe GD; Rumley A; Wallace M; Menday AP
Haemostasis; 1996; 26(2):90-7. PubMed ID: 9119288
[TBL] [Abstract][Full Text] [Related]
16. Dermatan sulphate as an antithrombotic drug.
Nenci GG
Pathophysiol Haemost Thromb; 2002; 32(5-6):303-7. PubMed ID: 13679662
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens.
Sabry A; Taha M; Nada M; Al Fawzan F; Alsaran K
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):57-62. PubMed ID: 20523166
[TBL] [Abstract][Full Text] [Related]
18. Citrate versus heparin anticoagulation in chronic haemodialysis patients.
Janssen MJ; Huijgens PC; Bouman AA; Oe PL; Donker AJ; van der Meulen J
Nephrol Dial Transplant; 1993; 8(11):1228-33. PubMed ID: 8302461
[TBL] [Abstract][Full Text] [Related]
19. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy.
Vitale C; Verdecchia C; Bagnis C; Ganzaroli M; Giorcelli G; Marangella M
J Nephrol; 2008; 21(2):205-12. PubMed ID: 18446715
[TBL] [Abstract][Full Text] [Related]
20. Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.
Matsuo T; Yamada T; Yamanashi T; Kodama K
Clin Lab Haematol; 1989; 11(3):213-9. PubMed ID: 2686903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
